AusCann Group Holdings Ltd: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
AusCann Group Holdings Ltd researches, develops, and commercializes various cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. It offers tetrahydrocannabinol and cannabidiol powder-based hard-shell capsules using Neuvis technology platform for the treatment of pain and related indications; CPAT-01, a liquid, oral veterinary medicine to treat pain and inflammation in dogs; and DermaCann, a liquid oral oil formulation containing CBD for healthy skin and immune function in dogs. The company is headquartered in West Perth, Australia. | AusCann Group Holdings Ltd researches, develops, and commercializes various cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. It offers tetrahydrocannabinol and cannabidiol powder-based hard-shell capsules using Neuvis technology platform for the treatment of pain and related indications; CPAT-01, a liquid, oral veterinary medicine to treat pain and inflammation in dogs; and DermaCann, a liquid oral oil formulation containing CBD for healthy skin and immune function in dogs. The company is headquartered in West Perth, Australia. | ||
__INDEX__ | |||
Latest revision as of 14:02, 15 August 2022
SummaryEdit
AusCann Group Holdings Ltd researches, develops, and commercializes various cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. It offers tetrahydrocannabinol and cannabidiol powder-based hard-shell capsules using Neuvis technology platform for the treatment of pain and related indications; CPAT-01, a liquid, oral veterinary medicine to treat pain and inflammation in dogs; and DermaCann, a liquid oral oil formulation containing CBD for healthy skin and immune function in dogs. The company is headquartered in West Perth, Australia.